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Clinical Course of a Covid-19 Patient with Gastrointestinal 
Symptoms- A Case Report 
Sidra Agarwal,1 Hemanshi Mistry.2 
Abstract 
Background: COVID-19 most commonly presents with respiratory symptoms. However, it can involve the gastrointestinal tract causing symptoms like 
diarrhea and the resultant shedding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in feces. This is due to the virus adhering to 
angiotensin-converting enzyme 2 receptors largely present in the gastrointestinal tract. This case report recommends routine stool Real-Time Reverse 
Polymerase Chain Reaction (rRT-PCR) testing for patients presenting with gastrointestinal symptoms. The Case: A healthy 36-year-old male healthcare 
worker in New York who tested positive for SARS-CoV-2 infection through rRT-PCR of the nasopharyngeal swab. After 7 days of convalescence, he recovered 
from influenza like symptoms after which he predominantly developed diarrhea, nausea, vomiting and extreme fatigue. Cough was the only lower 
respiratory symptom during the 3rd week of the clinical course. Anosmia or ageusia preceding the onset of respiratory symptoms was also reported. Due 
to the outbreak of the pandemic and New York being the epicenter at the time, the patient was recommended to self-isolate with supportive management 
through antipyretics and electrolyte replacement. Conclusion: This case highlights a SARS-CoV-2 PCR positive patient with predominant gastrointestinal 
symptoms. The reports regarding virus shedding in feces suggest that SARS-CoV-2 could be transmitted via fecal-oral route and thus routine stool rRT-PCR 
testing can aid in transmission-based precautions. Furthermore, reports of viral ribonucleic acid present in the stool, suggests direct infectivity of the virus 
on the intestinal tract. Therefore, screening in patients with only gastrointestinal symptoms can potentially help to contain the virus spread. 
 




A novel coronavirus, severe acute respiratory syndrome coronavirus 2 
(SARS‐CoV‐2), with rapid spread worldwide, has now become a public 
health emergency.1 A growing number of publications are shedding 
light on the frequency and nature of the gastrointestinal symptoms of 
coronavirus disease-2019 (COVID-19).2 SARS-CoV-2 is thought to make 
its way into the gastrointestinal tract by adhering its spike proteins to 
angiotensin-converting enzyme 2 (ACE2) receptors, which are located 
in the lungs but also widely present in the gastrointestinal tract.3 
 
A review article noted that diarrhea and vomiting was the most common 
symptom in children, diarrhea in adults whereas abdominal pain and 
gastrointestinal bleeding was mostly seen in severely ill patients, and 
it also showed that the incidence of gastrointestinal symptoms was 
higher in the later than in the early stages of the clinical course.4 
 
Han et al, described a unique subgroup of COVID-19 patients with mild 
disease severity marked by the presence of digestive symptoms. This 
study demonstrated that the time between symptom onset and viral 
clearance was significantly longer in this subgroup and this longer 
disease course might reflect a higher viral burden in comparison to 
those with only respiratory symptoms.5 Parasa et al, also found that 
these patients are more likely to test positive for COVID-19 viral 
Ribonucleic acid (RNA) in the stool, suggesting direct infectivity of the 
virus on the intestinal tract.2 
 
A study by Xiao et al, highlighted the clinical significance of testing viral 
RNA in feces by real-time reverse transcriptase polymerase chain 
reaction (rRT-PCR).6 According to the Centers for Disease Control and  
 
Prevention (CDC) guidance for the disposition of patients with SARS-
CoV-2, the decision to discontinue transmission-based precautions for 
hospitalized patients with SARS-CoV-2 was dependent on the negative 
results of Real-Time Reverse Polymerase Chain Reaction (rRT-PCR) 
testing for SARS-CoV-2 from at least 2 sequential respiratory tract 
specimens collected ≥24 hours apart.7 It was found that in more than 
20% of patients, although the viral RNA in the respiratory tract were 
negative, it remained positive in feces indicating that the viral 
gastrointestinal infection and potential fecal-oral transmission 8 can last 
even after the virus has cleared from the respiratory tract.2 It has been 
recommended that rRT-PCR testing for SARS-CoV-2 from feces should be 
performed routinely due to the high prevalence of positive stools in 
patients with COVID-19.5 Here we described a case of a healthcare 
worker with predominant gastrointestinal symptoms who tested 
positive for COVID-19. We obtained written consent, and the Human 
Infection with COVID-19 Person Under Investigation (PUI) and Case 
Report Form was filled by the patient. 
 
Highlights: 
 This case report highlights another possible option for the 
pathophysiology of the SARS-CoV-2 infection. 
 It presented a case of predominant gastrointestinal symptoms in 
COVID-19 compared to lower respiratory symptoms. 
 The case report depicts importance of rRT-PCR testing for fecal-oral 
transmission. 
 Further research is needed to probe the role of fecal-oral 
transmission. 
Case Report  
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The Case 
An otherwise healthy 36-year-old male, healthcare worker in New York, 
with no recent travel history and no history of diabetes mellitus, 
coronary artery disease, or hypertension presented to an urgent care 
with flu like symptoms (Figure 1). 
 
The patient first noticed flu-like symptoms such as low-grade fever, 
chills, muscle aches, sore throat, weakness, and headache after 
possible healthcare contact with a COVID-19 case-patient. Vitals showed 
a temperature of 100.4 °F, blood pressure of 124/78 mmHg, heart rate 
of 95 beats per minute, and respiratory rate of 18 and pulse oxygen 
saturation of 97%. The National Early Warning Score (NEWS) was 1 (from 
0 to 20, the score is related with clinical risk). The physical examination 
was normal otherwise. He was tested negative for Influenza Rapid Ag 
using the OSOM Ultra Flu Influenza A & B Test: Sekisui Diagnostics, LLC. 
A nasopharyngeal swab sample was performed on Day 1 of onset of 
symptoms to check for SARS-CoV-2 infection by using CDC 2019-nCoV 
Real-Time RT-PCR Diagnostic Panel protocol (CDC, Atlanta, Georgia, USA) 
that confirmed SARS-CoV-2 by positive result on polymerase chain 
reaction assay. No Radiological study (radiography or chest scan) was 
performed on the patient. He was placed under home isolation with 
daily monitoring for development of cough, dyspnea along with daily 
temperature and vital sign measurements. The patient was not 
prescribed antibiotics. Treatment during this time was largely 
supportive which included Acetaminophen 1000 mg every 8 hours as 
needed and a multivitamin a day. The patient started to notice 
improvement in his flu-like symptoms towards the end of the first week. 
 
 




On Day 7, the patient noticed sudden reappearance of fever, aches, 
chills, and weakness. He developed symptoms of diarrhea associated 
with nausea, vomiting, and complete loss of taste and smell. The 
patient mostly had watery stools that occurred 3-4 times a day for 1 
week, no blood or mucus. He also had loss of appetite, inability to 
tolerate solid foods, significant weakness, and fatigue with no energy 
to perform daily activities. The patient did not undergo coproscopy and 
coproculture. There was no history of other infectious diseases such as 
HIV. There was no epidemiological link related to gastrointestinal 
symptoms such as food consumption, intoxication or fast food. The 
patient was on electrolyte replacement and plenty of oral fluids 
throughout the course of the illness due to gastrointestinal symptoms. 
 
He had no cough, shortness of breath or chest pain. Vitals signs were: 
temperature 100.6 °F, blood pressure 95/60 mmHg, heart rate 104 beats 
per minute, respiratory rate 19, and pulse oxygen saturation of 99%. 
The NEWS was 4. At home supportive management with electrolyte 
replacement and plenty of oral fluids was the mainstay therapy. 
 
In the 3rd week of convalescence at day 16, the patient developed a 
new onset cough but no shortness of breath, difficulty breathing or 
chest pain. He continued to have loss of taste and smell, but the 
diarrhea resolved. 
 
At day 22, symptoms completely resolved but the patient continued to 
have some weakness and lethargy. The patient was not prescribed any 
antibiotics and did not require hospitalization, mechanical 
ventilation/intubation or ECMO (Table 1). 
 
After the resolution of symptoms, the patient was followed-up by using 
CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel protocol (CDC, 
Atlanta, Georgia, USA) on Day 40 after the initial symptoms to assess 
clearance of viremia which was negative. He also underwent SARS-CoV-
2 AB IgG test on day 138 that was positive indicating adaptive immune 
response to SARS-CoV-2. 
Table 1. COVID-19 patient convalescence and findings 
 
Duration Presentation 
Day 1-6 Low grade fever, chills, muscle aches, sore throat, 




Worse again with sudden reappearance of fever, aches, 
chills, weakness, non-bloody watery diarrhea, nausea, 
vomiting, anosmia, ageusia, loss of appetite, fatigue. 
Day 15-21 
 








This case report describes a COVID-19 positive patient who initially 
presented with flu-like symptoms which was followed by diarrhea, 
nausea, vomiting, loss of appetite that lasted for most part of the 
illness with cough being the only respiratory symptom. 
 
Receptor-mediated viral entry into a host cell is the first step of viral 
infection. SARS‐CoV‐2 enters cells via the angiotensin-converting 
enzyme 2 (ACE2) receptor, and this receptor is expressed in the 
glandular epithelial cells of the stomach, duodenum, rectum, and via 
the absorptive enterocytes of ileum and colon.9 These receptors are 
rarely found in esophageal epithelium because the esophagus is lined 
by the squamous epithelium and ACE2 receptor mainly targets the 
glandular epithelium. Viral nucleocapsid protein staining in the gastric, 
duodenal, and rectal epithelium confirmed the presence of SAR-COV-2 
in these locations. Although the viral RNA could be detected in the 
esophageal mucosa, failure to stain the viral nucleocapsid protein 
shows low infectivity in the esophagus. In addition, ACE2 expression is 
higher in the gastrointestinal tract than in the lungs.10 Patients with 
digestive symptoms have more virus in the gut based on the stool RNA 
testing, and thus potentially greater damage to the gut mucosa. 
 Low Grade Fever 
 Muscle 
 Aches 






 Loss of taste and smell 
 Loss of appetite 
o Brief new Onset Cough 
o Resolution of gastrointestinal symptoms 
o No shortness of breath and chest pain 
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The tissue tropism of the SARS-CoV-2 in the intestinal tract has a major 
role to play in the clinical presentation and viral transmission.11 In a 
systematic review and pooled analysis of published and preprint 
literature of SARS-CoV-2 infection and gastrointestinal symptoms, it was 
found that approximately 10% to 12% of patients with COVID-19 
experience gastrointestinal symptoms, such as diarrhea (7.4%) and 
nausea or vomiting (4.6%).2 Similarly, with our case, diarrhea was 
mostly watery without any blood or mucus and abdominal pain was 
minimal in most cases.2 
 
The longer disease course in patients with digestive symptoms might 
be because of higher viral burden in these patients in comparison to 
those with only respiratory symptoms.12 As the intestinal wall is 
invaded by SARS-CoV-2, there may be increased permeability and 
diminished barrier function allowing easier invasion of pathogens 
across the intestinal surface area.5  Recent evidence has shown that 
fecal nucleic acid is readily detected in the stool of patients with COVID-
19 and rectal swabs are also positive in some patients.4 Han et al, stated 
that given the high prevalence of positive stools and the correlation 
between diarrhea and stool positivity, routine rRT-PCR testing of feces 
should be recommended in COVID-19 patients, especially those 
presenting with digestive symptoms.13 
 
Recommended management for these cases is based on supportive 
measurements,5 as described here. The patient was not exposed to any 
other potential cause of gastrointestinal symptoms and the length of 
duration of his gastrointestinal symptoms without any comorbidities 
calls the attention towards the role of this potential way of infection. 
 
More research is needed to identify the reliability of testing suspect 
patients based on oropharyngeal samples only vs. the addition of stool 
samples. Can a patient have a respiratory resolution (a negative test) 
but the virus can continue its pathogenesis in the gastrointestinal 
system? Can the patient restart respiratory symptoms through 
reinfection? These are a few questions that we are pending to answer. 
 
Conclusion 
Our case report highlights predominant gastrointestinal involvement in 
a COVID-19 patient due to intestinal tropism of SARS-CoV-2. Studies 
regarding virus shedding in feces suggest that SARS-CoV-2 could be 
transmitted via the fecal-oral route and thus routine stool rRT-PCR 
testing can aid in transmission-based precautions among patients with 
SARS-CoV-2 infection. Furthermore, COVID-19 viral RNA present in the 
stool, suggests direct infectivity of the virus on the intestinal tract. We 
would also recommend screening for SARS-CoV-2 infection in patients 
presenting with only gastrointestinal symptoms and possible 
symptomatic management. 
 
Case Report  
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